other

Human GFAP (Glial Fibrillary Acidic Protein) CLIA Kit

MBS2530973

48-Strip-Wells

450 USD

CLIA Kit

Human GFAP (Glial Fibrillary Acidic Protein) CLIA Kit

[GFAP (Glial Fibrillary Acidic Protein)]

[glial fibrillary acidic protein; Glial fibrillary acidic protein; glial fibrillary acidic protein; glial fibrillary acidic protein]

[GFAP]

[GFAP; GFAP; ALXDRD; GFAP]

GFAP_HUMAN

Human

432

This kit recognizes natural and recombinant GFAP. No significant cross-reactivity or interference between GFAP and analogues was observed.

Typical Testing Data/Standard Curve (for reference only)

Assay Type: Sandwich. Detection Range: 62.5-4000pg/mL. Sensitivity: Min: 37.5pg/mL; Max: 4000pg/mL

Intended Uses: This CLIA kit applies to the in vitro quantitative determination of GFAP concentrations in serum, plasma and other biological fluids. Principle of the Assay This kit uses Sandwich-CLIA as the method. The micro CLIA plate provided in this kit has been pre-coated with an antibody specific to GFAP. Standards or samples are added to the appropriate micro CLIA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for GFAP and Avidin-Horseradish Peroxidase (HRP) conjugate is added to each micro plate well successively and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain GFAP, biotinylated detection antibody and Avidin-HRP conjugate will appear fluorescence. The Relative light unit (RLU) value is measured spectrophotometrically by the Chemiluminescence immunoassay analyzer. The RLU value is positively associated with the concentration of GFAP. You can calculate the concentration of GFAP in the samples by comparing the RLU value of the samples to the standard curve.

251802

AAB22581.1

49,508 Da

Jak-STAT Signaling Pathway (83077); Jak-STAT Signaling Pathway (488); Neural Crest Differentiation Pathway (672460); Nuclear Signaling By ERBB4 Pathway (1269499); Signal Transduction Pathway (1269379); Signaling By ERBB4 Pathway (1269496); Spinal Cord Injury Pathway (739007)

This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008]

GFAP: a class-III intermediate filament protein. A cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. An additional transcript variant isoform has been described, but its full length sequence has not been determined. Protein type: Cytoskeletal. Chromosomal Location of Human Ortholog: 17q21. Cellular Component: membrane; cytoplasm; intermediate filament; cytosol; myelin sheath. Molecular Function: integrin binding; protein binding; structural constituent of cytoskeleton; kinase binding. Biological Process: extracellular matrix organization and biogenesis; Bergmann glial cell differentiation; regulation of neurotransmitter uptake; response to wounding; neurite regeneration; intermediate filament organization; astrocyte development. Disease: Alexander Disease

48-Strip-Wells

450 USD

96-Strip-Wells

535

5x96-Strip-Wells

2255

10x96-Strip-Wells

3975